Eli Lilly's Oral GLP-1 Therapy Sustains Weight Loss Post-Injection
TL;DR Summary
Eli Lilly's oral GLP-1 receptor agonist, orforglipron, successfully maintained weight loss in a Phase 3 trial after patients switched from injectable therapies, leading Lilly to submit it for FDA approval as a treatment for obesity.
- Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly
- Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound CNBC
- People Are Already Taking This Unapproved New Weight-Loss Drug WIRED
- Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug The New York Times
- Lilly's obesity pill largely maintains weight lost on injectable GLP-1s Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
22 min
vs 22 min read
Condensed
99%
4,383 → 35 words
Want the full story? Read the original article
Read on Eli Lilly